[go: up one dir, main page]

CO2017007940A2 - Péptidos antagonistas prgc - Google Patents

Péptidos antagonistas prgc

Info

Publication number
CO2017007940A2
CO2017007940A2 CONC2017/0007940A CO2017007940A CO2017007940A2 CO 2017007940 A2 CO2017007940 A2 CO 2017007940A2 CO 2017007940 A CO2017007940 A CO 2017007940A CO 2017007940 A2 CO2017007940 A2 CO 2017007940A2
Authority
CO
Colombia
Prior art keywords
prgc
antagonist peptides
compounds
formula
antagonist
Prior art date
Application number
CONC2017/0007940A
Other languages
English (en)
Inventor
Kazimierz Wisniewski
Guangcheng Jiang
K Aleksandr Rabinovich
J Javier Sueiras-Diaz
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of CO2017007940A2 publication Critical patent/CO2017007940A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)

Abstract

Esta revelación se relaciona con compuestos de la fórmula o una sal farmacéuticamente aceptable de los mismos: en los cuales m, p, A, Ar’, Ar2, Ar3, R’, R2, y R3 se definen en la especificación. Los compuestos de la fórmula (1) podrán usarse como antagonistas PRGC y podrán usarse para tratar la migraña.
CONC2017/0007940A 2015-01-06 2017-08-04 Péptidos antagonistas prgc CO2017007940A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562100371P 2015-01-06 2015-01-06
PCT/EP2016/050110 WO2016110499A1 (en) 2015-01-06 2016-01-06 Cgrp antagonist peptides

Publications (1)

Publication Number Publication Date
CO2017007940A2 true CO2017007940A2 (es) 2017-10-31

Family

ID=55071041

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0007940A CO2017007940A2 (es) 2015-01-06 2017-08-04 Péptidos antagonistas prgc

Country Status (33)

Country Link
US (1) US9969775B2 (es)
EP (1) EP3242882B1 (es)
JP (1) JP6929227B2 (es)
KR (1) KR102713739B1 (es)
CN (1) CN107207567B (es)
AR (1) AR103499A1 (es)
AU (1) AU2016206059B2 (es)
BR (1) BR112017013413A2 (es)
CL (1) CL2017001761A1 (es)
CO (1) CO2017007940A2 (es)
DK (1) DK3242882T3 (es)
EA (1) EA032082B1 (es)
ES (1) ES2924410T3 (es)
HR (1) HRP20220941T1 (es)
HU (1) HUE059379T2 (es)
IL (1) IL252903B (es)
JO (1) JO3669B1 (es)
LT (1) LT3242882T (es)
MA (1) MA41311B1 (es)
MD (1) MD3242882T2 (es)
MX (1) MX387920B (es)
MY (1) MY196439A (es)
PH (1) PH12017501214A1 (es)
PL (1) PL3242882T3 (es)
PT (1) PT3242882T (es)
RS (1) RS63467B1 (es)
SA (1) SA517381865B1 (es)
SG (1) SG11201705306UA (es)
SI (1) SI3242882T1 (es)
TN (1) TN2017000248A1 (es)
TW (1) TWI717331B (es)
UA (1) UA121490C2 (es)
WO (1) WO2016110499A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3707157A4 (en) * 2017-11-06 2021-08-18 Auckland Uniservices Limited PEPTIDIC CONJUGATES AS ANAGONISTS OF THE CGRP RECEIVER, THEIR PREPARATION METHODS AND THEIR USES
EP4647082A1 (en) 2024-05-08 2025-11-12 NUVIE BIO, Inc. Pharmaceutical composition comprising a cgrp receptor antagonist for the treatment of acute migraine
WO2025202938A1 (en) 2024-03-26 2025-10-02 Nuvie Bio, Inc. Pharmaceutical composition comprising a cgrp receptor antagonist for the treatment of acute migraine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268474B1 (en) * 1998-04-30 2001-07-31 Creighton University Peptide antagonists of CGRP-receptor superfamily and methods of use
TW200533398A (en) 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
US20060004185A1 (en) * 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
JP2008515895A (ja) * 2004-10-07 2008-05-15 メルク エンド カムパニー インコーポレーテッド Cgrp受容体拮抗薬
US20080161232A1 (en) * 2005-01-17 2008-07-03 Jerini Ag C5a Receptor Antagonist
CA2599925A1 (en) * 2005-03-14 2006-09-21 Merck & Co., Inc. Cgrp receptor antagonists
US8168592B2 (en) * 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
WO2007054809A2 (en) * 2005-11-14 2007-05-18 Rinat Neuroscience Corp. Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
AU2007258294A1 (en) * 2006-06-13 2007-12-21 Vertex Pharmaceuticals Incorporated CGRP receptor antagonists
WO2013112912A1 (en) 2012-01-26 2013-08-01 Soares Christopher J Peptide antagonists of the calcitonin cgrp family of peptide hormones and their use

Also Published As

Publication number Publication date
JO3669B1 (ar) 2020-08-27
MD3242882T2 (ro) 2022-10-31
PT3242882T (pt) 2022-08-09
HRP20220941T1 (hr) 2022-10-28
SA517381865B1 (ar) 2021-09-15
MA41311A (fr) 2017-11-14
MY196439A (en) 2023-04-11
DK3242882T3 (en) 2022-08-08
WO2016110499A1 (en) 2016-07-14
TWI717331B (zh) 2021-02-01
IL252903B (en) 2021-01-31
ES2924410T3 (es) 2022-10-06
MX387920B (es) 2025-03-19
US9969775B2 (en) 2018-05-15
US20180002378A1 (en) 2018-01-04
CL2017001761A1 (es) 2018-01-26
CN107207567B (zh) 2021-11-23
MX2017008893A (es) 2017-10-25
JP6929227B2 (ja) 2021-09-01
SG11201705306UA (en) 2017-07-28
HUE059379T2 (hu) 2022-11-28
SI3242882T1 (sl) 2022-09-30
EP3242882B1 (en) 2022-05-04
NZ732771A (en) 2024-07-05
PH12017501214A1 (en) 2018-01-08
AR103499A1 (es) 2017-05-17
KR102713739B1 (ko) 2024-10-04
EA032082B1 (ru) 2019-04-30
KR20170102302A (ko) 2017-09-08
JP2018505213A (ja) 2018-02-22
CA2973041A1 (en) 2016-07-14
UA121490C2 (uk) 2020-06-10
EP3242882A1 (en) 2017-11-15
IL252903A0 (en) 2017-08-31
CN107207567A (zh) 2017-09-26
AU2016206059A1 (en) 2017-07-20
AU2016206059B2 (en) 2019-07-25
TN2017000248A1 (en) 2018-10-19
PL3242882T3 (pl) 2022-10-31
EA201791456A1 (ru) 2018-01-31
BR112017013413A2 (pt) 2018-01-09
LT3242882T (lt) 2022-08-25
TW201630929A (zh) 2016-09-01
RS63467B1 (sr) 2022-08-31
MA41311B1 (fr) 2022-10-31

Similar Documents

Publication Publication Date Title
ECSP20025899A (es) Compuestos útiles para inhibir a cdk7
CL2018003290A1 (es) Amidas heterocíclicas útiles como moduladores de proteínas (divisional de solicitud cl 2850-2018).
CY1121413T1 (el) Διυδροπυρρολοπυριδινης αναστολεις ror-γαμμα
EA201792536A1 (ru) Триазоловые агонисты рецептора apj
MX381588B (es) N-(fenilsulfonil)benzamidas y compuestos relacionados como inhibidores de bcl-2.
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
MX379155B (es) Compuestos que inhiben la proteína mcl-1.
MX374729B (es) Compuestos de heteroarilo o arilo biciclicos fusionados y su uso como inhibidores irak4.
EA201692249A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
EA201790078A1 (ru) Ингибиторы mnk и связанные с ними способы
MX377916B (es) Compuestos 4-amino-imidazoquinolina.
EA201591420A1 (ru) Гетероарильные соединения и их применение
MX381487B (es) Ciertos inhibidores de la proteina quinasa.
AR103680A1 (es) Inhibidores selectivos de bace1
EA201692267A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
EA201692266A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
EA201692268A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
EA201692265A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
BR112015020139A2 (pt) compostos terapêuticos e usos dos mesmos
MX390051B (es) Antagonistas de ep4.
EA201692470A1 (ru) Фармацевтические комбинации
EA201692474A1 (ru) Производные 1-(циклопент-2-ен-1-ил)-3-(2-гидрокси-3-(арилсульфонил)фенил)мочевины в качестве ингибиторов cxcr2
EA201692289A1 (ru) Замещенные [1,2,4]триазольные и имидазольные соединения в качестве фунгицидов
EA201700356A1 (ru) Новые циклопропанбензофуранилпиридопиразиндионы